Ask AI
Management of Progressive BTC

CE / CME

Management of a Patient With Progressive Biliary Tract Cancer After Standard of Care Gemcitabine/Cisplatin Plus an Immune Checkpoint Inhibitor

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: December 30, 2025

Expiration: June 29, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following patients with BTC or gastroesophageal adenocarcinoma (GEA) would be eligible for treatment with the bispecific HER2-directed antibody zanidatamab in the advanced disease setting?

2.

A 55-year-old woman and previous heavy smoker is diagnosed with metastatic BTC. She has a history of cardiac abnormalities that are controlled with medications. She receives first-line treatment with gemcitabine and cisplatin (gem/cis) plus pembrolizumab but experiences disease progression with multiple new lesions in the peritoneum. A biopsy of the new lesions reveal HER2 amplification (IHC 3+).


After discussions of the safety and efficacy of the available FDA-approved HER2-directed options vs chemotherapy in the second-line disease setting with this patient and her caregiver, the decision was made to start treatment with zanidatamab (20 mg/kg, intravenously, given once every 2 weeks).

Which of the following adverse events would you be sure to discuss with her before she starts treatment with zanidatamab?